New crossmatch technique eliminates interference by humanized and chimeric monoclonal antibodies
| Autor: | A.B. Milgrom, Nancy G. Higgins, Christopher M. Bearden, Mark D. Pescovitz, R A Sidner, Benita K. Book, Avinash Agarwal |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Male
Daclizumab Transplantation Conditioning medicine.drug_class Antibodies Neoplasm Enzyme-Linked Immunosorbent Assay Human leukocyte antigen Humanized antibody Monoclonal antibody Antibodies Monoclonal Humanized Antibodies Monoclonal Murine-Derived Antigen Reference Values medicine Humans Blood Transfusion Alemtuzumab Transplantation Transplantation Chimera biology business.industry Chimera Histocompatibility Testing Antibodies Monoclonal Virology Infliximab Immunoglobulin G Immunology biology.protein Surgery Antibody business Rituximab medicine.drug |
| Zdroj: | Transplantation proceedings. 37(2) |
| ISSN: | 0041-1345 |
| Popis: | Humanized and chimeric antilymphocyte antibodies (Ab) are used to prevent and treat rejection and for treatment of human disease. Rituximab (RIT, anti-CD20), daclizumab (DAC; anti-CD25), alemtuzumab (ALE; anti-CD52), or infliximab (IFX) may interfere with Ab detection methods such as complement-dependent cytotoxicity (CDC) and flow cytometric crossmatch (FCXM). These agents are recognized as anti-human Ab or fix complement and are not differentiated from anti-allo-Ab. A new enzyme-linked immunosorbent assay crossmatch (XM) utilizing class I and II HLA antigens from donor cells called Transplant Monitoring System (TMS; GTI, Waukesha, Wisc) potentially precludes interference by eliminating non-major histocompatability complex antigens. To test this, normal sera (nonsensitized volunteers) were supplemented with 0.1 or 10 microg/mL of RIT, DAC, IFX or ALE, and were tested using three methods: the TMS T-cell CDCXM with antihuman globulin (AHG); and B-cell CDCXM without AHG; and FCXM with mean channel shifts of 45 and 150 indicating positive T-cell and B-cell crossmatch, respectively. No reactivity occurred with normal sera using any crossmatch technique. At 0.1 and 10 microg/mL, RIT interfered with CDC B-cell, but not T-cell crossmatch. RIT at 10, but not 0.1 microg/mL interfered with B-cell FCXM. No interference occurred with RIT in T-cell FCXM or TMS. ALE interfered with B-cell and T-cell CDC and FCXM but neither class I nor II TMS. DAC did not interfere with CDC or FCXM at 0.1 microg/mL, but gave false positive B-cell FCXM and CDCXM with some samples. No interference by DAC occurred using TMS. TMS may be useful to differentiate de novo donor-specific Ab after treatment with humanized or chimeric Ab. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect